Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Bruner, Deborah Watkins

Nrg Oncology Foundation, Inc.
United States

NRG Oncology NCORP Research Base-BIQSFP 3UG1CA189867-11S2 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Bruner, Deborah Watkins

Nrg Oncology Foundation, Inc.
United States

NRG Oncology NCORP Research Base-BIQSFP 3UG1CA189867-11S2 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Bryan, Angela

University Of Colorado
United States

Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC 5R01CA284860-03 Brennan Streck, Ph.D., RN, M.P.H.
Bryan, Angela

University Of Colorado
United States

Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC 5R01CA284860-03 Brennan Streck, Ph.D., RN, M.P.H.
Bryan, Angela

University Of Colorado
United States

Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC 5R01CA284860-03 Brennan Streck, Ph.D., RN, M.P.H.
Bryan, Angela

University Of Colorado
United States

Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THC 5R01CA284860-03 Brennan Streck, Ph.D., RN, M.P.H.
Buczynski, Matthew Wallace

Virginia Polytechnic Inst And St Univ
United States

Anti-nociceptive actions of CART II in chemotherapy-induced peripheral neuropathy 5R01CA284075-03 Rachel Altshuler, Ph.D.
Buczynski, Matthew Wallace

Virginia Polytechnic Inst And St Univ
United States

Anti-nociceptive actions of CART II in chemotherapy-induced peripheral neuropathy 5R01CA284075-03 Rachel Altshuler, Ph.D.
Buis, Lorraine R

University Of Michigan At Ann Arbor
United States

MyGI Diet for Colorectal Cancer Prevention 5R01CA255743-04 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Burgess, Mark Thomas

Sloan-Kettering Inst Can Research
United States

Clinical assessment of radiotherapy-induced vaginal toxicity with multiparametric ultrasound imaging 5R21CA290252-02 Goli Samimi, Ph.D., M.P.H.
Buszczak, Michael

Ut Southwestern Medical Center
United States

Developing ribosome biogenesis inhibitors for the prevention of cancer 5UG3CA290312-02 Kajal Biswas, Ph.D.
Butler, Kathleen Yost

Corewell Health
United States

Cancer Research Consortium of West Michigan (CRCWM) 3UG1CA189860-11S1 Vanessa A. White, M.P.H.
Butler, Kathleen Yost

Corewell Health
United States

Cancer Research Consortium of West Michigan (CRCWM) 3UG1CA189860-11S1 Vanessa A. White, M.P.H.
Butryn, Meghan

Drexel University
United States

Efficacy of a multi-level intervention designed to promote adherence to WCRF/AICR dietary guidelines for cancer prevention 1R01CA288323-01A1 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Cai, Long

California Institute Of Technology
United States

Understanding the role of tumor microenvironment in low grade glioma progression to malignancy 4U01CA294551-02 Sidney Fu, M.D.